Pioneering A Novel Medicine For Fibrosis

We are developing a novel medicine to prevent, heal, and slow organ scarring due to fibrotic disease.

Read more about us

AM1476 is our highly selective, peripheral-acting 5‑HT2B receptor antagonist

Read more

AM1476 offers a unique dual-action potential to treat both skin and lung manifestations of systemic sclerosis

Read more

AM1476 is Phase II ready, supported by Phase I and preclinical proof-of-concept studies

Read more